Celgene Stock

CELG

Delayed Nasdaq Other stock markets 01:00:00 21/11/2019 +04			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

15/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

on all subscriptions*

Enjoy this offer

* See conditions under "Our services"

News in other languages: Celgene

07/04/21	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
25/03/21	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
02/02/21	BX Swiss AG startet Handel in neuem Bondsegment
07/07/20	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
03/07/20	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 66.85B 61.62B 57.74B 108B 7,376B 110B 735B 285B 3,556B 289B 283B 12,363B	P/E Ratio 2017	28.7x	P/E Ratio 2018	11.6x
Enterprise Value	91.26B 79.19B 73B 68.4B 128B 8,738B 130B 871B 337B 4,212B 343B 335B 14,645B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

15/06/23	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/09/21	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
22/06/21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
23/02/21	Celgene Corporation Issues Notice of Redemption of Notes	CI
04/02/21	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
05/01/21	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
23/12/20	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
05/11/20	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
23/09/20	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
22/09/20	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
26/03/20	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
11/03/20	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
04/03/20	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

28/02/23	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
25/08/22	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
29/07/22	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
25/02/22	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
04/08/21	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.28B 10.4B 9.75B 18.21B 1,245B 18.59B 124B 48.04B 600B 48.81B 47.76B 2,087B	15.28B 13.26B 12.22B 11.45B 21.4B 1,463B 21.85B 146B 56.45B 705B 57.36B 56.13B 2,452B
Net income	2.94B 2.55B 2.35B 2.2B 4.12B 282B 4.2B 28.05B 10.86B 136B 11.04B 10.8B 472B	4.05B 3.51B 3.24B 3.03B 5.67B 387B 5.78B 38.61B 14.95B 187B 15.19B 14.86B 649B
Net Debt	3.79B 3.29B 3.03B 2.84B 5.31B 363B 5.42B 36.19B 14.01B 175B 14.24B 13.93B 609B	14.22B 12.34B 11.38B 10.66B 19.92B 1,362B 20.33B 136B 52.54B 656B 53.39B 52.24B 2,282B

Celgene Stock

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile